Exoskeleton-Assisted Therapy for Upper Limb Motor Recovery in Early Subacute Stroke: Evidence from a Multicenter Randomized Controlled Trial

Highlights

• Exoskeleton-assisted robot-assisted therapy (RAT) significantly outperforms conventional rehabilitation in motor impairment recovery for subacute stroke patients.
• The robotic group achieved a median Fugl-Meyer Assessment for Upper Limb (FMA-UL) improvement 22 points higher than the control group.
• Patients receiving robotic therapy had 4.64 times higher odds of reaching the Minimal Clinically Important Difference (MCID).
• While motor impairment significantly improved, specific functional and participation measures showed comparable gains across both robotic and conventional cohorts.

Background

Upper limb motor impairment remains one of the most debilitating consequences of stroke, affecting approximately 80% of survivors in the acute phase and persisting in nearly 50% in the chronic phase. These impairments significantly limit activities of daily living (ADL), reduce quality of life, and increase the socioeconomic burden of stroke. The subacute phase—typically defined as the period from one week up to three months post-stroke—is widely regarded as the most critical window for neuroplasticity and functional reorganization.

Traditional rehabilitation strategies focus on high-intensity, task-oriented training. However, the labor-intensive nature of conventional therapy often limits the dosage and repetition necessary to drive significant neural changes. Robot-assisted therapy (RAT), particularly using exoskeleton systems, has emerged as a promising solution. Unlike end-effector robots, exoskeletons align with the patient’s anatomical joints, allowing for more precise control of multi-joint movements and facilitating complex, feedback-rich training environments. Despite the theoretical advantages, large-scale multicenter evidence for exoskeleton efficacy in the early subacute phase has been limited until the recent publication of the PowerUPS-Rehab study.

Key Content

Chronological Development of Robotic Evidence

The evolution of robot-assisted therapy has progressed through several distinct phases. Initial research in the early 2000s focused on end-effector devices (e.g., MIT-Manus), which showed modest benefits in chronic stroke patients. Over the last decade, focus shifted toward the subacute phase and more sophisticated exoskeleton designs. Major trials, such as the RATULS trial (2019), provided mixed results, highlighting that while robots could deliver high-dose therapy, they did not always surpass high-intensity manual therapy in functional outcomes. The Morone et al. (2026) study represents a significant methodological advancement by specifically targeting the early subacute window (<3 months) with multicenter oversight and a high-frequency intervention protocol.

Analysis of the Multicenter RCT (Morone et al., 2026)

The Italian PowerUPS-Rehab study was a landmark multicenter, single-blind randomized controlled trial conducted across eight specialized neurorehabilitation units. This trial addressed the critical need for high-quality evidence in the subacute phase, involving 94 randomized participants with moderate-to-severe upper limb impairment.

Methodological Framework

The intervention consisted of 25 sessions over five weeks (5 days per week). The robotic group received exoskeleton-assisted RAT integrated into usual care, while the control group received an equivalent duration of conventional rehabilitation. The primary outcome measure was the Fugl-Meyer Assessment for Upper Limb (FMA-UL), a gold standard for quantifying motor impairment. Secondary outcomes included measures of spasticity (Modified Ashworth Scale), activity capacity (Action Research Arm Test), and participation (Stroke Impact Scale).

Primary Outcomes: Impairment and MCID

The results were clinically significant. The robotic group showed a median improvement in the FMA-UL motor score that was 22 points higher than that of the control group (P<0.001). This is particularly noteworthy as the Minimal Clinically Important Difference (MCID) for the FMA-UL is typically considered to be 10 points. In this study, 68.4% of the robotic group achieved the MCID, compared to only 31.8% of the control group. The calculated odds ratio of 4.64 (95% CI, 1.83–11.8) underscores the potency of exoskeleton-assisted therapy in reversing motor impairment.

Secondary Outcomes: The Functionality Gap

Interestingly, while impairment (body structure and function) improved significantly in the robotic group, secondary outcomes related to actual task performance and activity did not show a statistically significant difference between groups at the 6-month follow-up. Both groups improved, but the robotic intervention did not provide an incremental benefit over conventional care in terms of spasticity reduction or ADL performance. This suggests that while exoskeletons are superior at restoring the underlying motor capacity, translating those gains into functional independence may require additional task-specific manual training or longer-term integration.

Safety and Feasibility

The trial reported a 12% dropout rate, which is relatively low for intensive subacute stroke trials. No serious adverse events related to the exoskeleton use were reported, confirming the safety and feasibility of deploying these complex systems in early post-stroke environments.

Expert Commentary

The Neural Rationale for Exoskeletons

From a mechanistic perspective, exoskeletons offer two primary advantages: precision and proprioception. By controlling the degree of freedom at each joint, the exoskeleton prevents compensatory movements (such as trunk leaning) that often hinder true motor recovery. Furthermore, the feedback-based nature of modern RAT systems—incorporating visual and haptic cues—strengthens the efference copy and reafference loop, which are vital for reinforcing neural pathways during the subacute window of heightened plasticity.

Clinical Applicability and Guidelines

Current international guidelines (such as the AHA/ASA and ESO guidelines) have moved toward recommending RAT as an adjunct to conventional therapy. The findings from Morone et al. (2026) provide a strong rationale for prioritizing exoskeleton interventions early in the subacute phase. However, health policy experts must weigh the high capital costs of robotic systems against the potential for reduced long-term disability costs. The study’s failure to show a superior functional benefit (ADL) compared to conventional therapy at 6 months highlights a controversy: Is impairment reduction enough to justify the investment if it does not immediately translate to better participation scores?

Limitations and Research Gaps

The single-blind design, while standard for rehabilitation trials where patients cannot be blinded to the intervention, introduces potential bias. Additionally, the study did not fully elucidate which patient subtypes (e.g., cortical vs. subcortical strokes) benefit most from exoskeleton assistance. Future research should employ neuroimaging markers (such as fMRI or DTI) to correlate motor improvements with specific patterns of brain reorganization.

Conclusion

The Italian PowerUPS-Rehab study provides robust multicenter evidence that exoskeleton-assisted robot therapy is a powerful tool for reducing upper limb motor impairment in early subacute stroke. With a nearly five-fold increase in the likelihood of achieving clinically significant motor recovery, the robotic approach represents a clear advance over purely conventional methods for impairment reduction. While the transition from motor gains to functional independence remains a complex challenge, the integration of exoskeleton technology into early stroke care protocols is increasingly supported by high-level evidence. Future efforts should focus on optimizing the transition from robotic impairment training to functional activity training to ensure that the gains seen on the Fugl-Meyer scale translate into improved quality of life for stroke survivors.

References

• Morone G, Pournajaf S, Iosa M, et al. Exoskeleton-Assisted Therapy Enhances Upper Limb Motor Recovery in Early Subacute Stroke: A Multicenter, Single-Blind Randomized Controlled Trial. Stroke. 2026;57(3). PMID: 41815092.
• Rodgers H, Bosomworth H, Krebs HI, et al. Robot assisted training for the upper limb after stroke (RATULS): a multicentre randomised controlled trial. Lancet. 2019;394(10192):51-62. PMID: 31122758.
• Mehrholz J, Pohl M, Platz T, Kugler J, Elsner B. Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. Cochrane Database Syst Rev. 2018;9(9):CD006876. PMID: 30175845.